Can a malaria drug help lung cancer patients stay on treatment longer?

NCT ID NCT00977470

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 22 times

Summary

This study tested whether adding hydroxychloroquine (a malaria drug) to the standard targeted therapy erlotinib could help delay resistance in people with advanced non-small cell lung cancer that has specific EGFR mutations. The trial enrolled 76 participants and measured how long the cancer stayed under control. The goal was to see if the combination could extend the time before the cancer started growing again.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Stanford Cancer Institute

Stanford, California, 94305, United States
University of Maryland

Baltimore, Maryland, 21201, United States
Yale Cancer Center

New Haven, Connecticut, 06519, United States

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER